OSI REPORTS DATA FROM STUDY OF PSN010

OSI Pharmaceuticals has initiated a Phase I clinical study of PSN010. PSN010 is a glucokinase activator (GKA) that is designed to rapidly lower blood glucose levels by increasing glucose uptake in the liver and increasing insulin secretion from the pancreas.

The single-center, double-blind study is scheduled to enroll up to 80 healthy volunteers. The single dose escalation study is designed to provide preliminary information on the safety, tolerability, pharmacokinetics and pharmacodynamics of PSN010. Study results will assist in facilitating the design of a multiple dose study in healthy subjects and a Phase II proof-of-concept clinical study in diabetes patients.